 |
|
Adding Tirofiban on Top of Recombinant Tissue Plasminogen Activator May Improve Clinical Outcome in Acute Stroke Patients
Ruhui Liu, Zhigang Liang, Wei Li, Yan Zhan, Luyao Xu, Shaowan Yang, Guomin Zheng, Li Jiang, Liwen Xie, Zhongwen Sun, Yinbao Hu
J Stroke. 2024;26(1):121-124. Published online 2024 Jan 30 DOI: https://doi.org/10.5853/jos.2023.02250
|
|
Citations to this article as recorded by
 Efficacy and safety of intravenous tirofiban versus standard medical treatment in acute ischemic stroke: A meta-analysis of randomized controlled trials
Gabriel de Almeida Monteiro, Antonio Mutarelli, Marianna Leite, Gabriel Marinheiro, Beatriz Araujo, Ocílio Ribeiro Gonçalves, Joaquim Francisco Cavalcante-Neto, Paulo Roberto Lacerda Leal, Keven Ferreira da Ponte, Eberval Gadelha Figueiredo, João Paulo Mo
Clinical Neurology and Neurosurgery.2024; 247: 108602. CrossRef Advancing stroke safety and efficacy through early tirofiban administration after intravenous thrombolysis: The multicenter, randomized, placebo-controlled, double-blind ASSET IT trial protocol
Chunrong Tao, Tianlong Liu, Jun Sun, Yuyou Zhu, Rui Li, Li Wang, Chao Zhang, Jianlong Song, Xiaozhong Jing, Thanh N Nguyen, Raul G Nogueira, Jeffrey L Saver, Wei Hu
International Journal of Stroke.2024;[Epub] CrossRef
|